{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:27:41Z","timestamp":1780414061480,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010870","name":"Qingdao Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["22-3-7-smjk-15-nsh"],"award-info":[{"award-number":["22-3-7-smjk-15-nsh"]}],"id":[{"id":"10.13039\/501100010870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pathogenic variants in BRCA genes play a crucial role in the pathogenesis of ovarian cancer. Intronic variants of uncertain significance (VUS) may contribute to pathogenicity by affecting splicing. Currently, the significance of many intronic variants in BRCA has not been clarified, impacting patient treatment strategies and the management of familial cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A retrospective study was conducted to analyze BRCA intronic VUS in a cohort of 707 unrelated ovarian cancer patients at a single institution from 2018 to 2023. Three splicing predictors were employed to analyze detected intronic VUS. Variants predicted to have splicing alterations were selected for further validation through minigene assays. Patient and familial investigations were conducted to comprehend cancer incidence within pedigrees and the application of poly (ADP-ribose) polymerase inhibitors (PARPi) by the patients. In accordance with the guidelines of the American College of Medical Genetics and Genomics (ACMG), the intronic VUS were reclassified based on minigene assay results and clinical evidence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>Approximately 9.8% (69\/707) of patients were identified as carriers of 67 different VUS in BRCA1\/2, with four intronic variants accounting for 6% (4\/67) of all VUS. Splicing predictors indicated potential splicing alterations in splicing for BRCA1 c.4358-2A&gt;G and BRCA2 c.475+5G&gt;C variants. Minigene assays utilizing the pSPL3 exon trapping vector revealed that these variants induced changes in splicing sites and frameshift, resulting in premature termination of translation (p. Ala1453Glyfs and p. Pro143Glyfs). According to ACMG guidelines, BRCA1 c.4358-2A&gt;G and BRCA2 c.475+5G&gt;C were reclassified as pathogenic variants. Pedigree investigations were conducted on patients with BRCA1 c.4358-2A&gt;G variant, and the detailed utilization of PARPi provided valuable insights into research on PARPi resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Two intronic VUS were reclassified as pathogenic variants. A precise classification of variants is crucial for the effective treatment and management of both patients and healthy carriers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-05597-y","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T09:02:44Z","timestamp":1706778164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reclassifying BRCA1 c.4358-2A\u2009&gt;\u2009G and BRCA2 c.475\u2009+\u20095G\u2009&gt;\u2009C variants from \u201cUncertain Significance\u201d to \u201cPathogenic\u201d based on minigene assays and clinical evidence"],"prefix":"10.1007","volume":"150","author":[{"given":"Ying","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhumei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"5597_CR1","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/humu.23626","volume":"39","author":"AN Abou Tayoun","year":"2018","unstructured":"Abou Tayoun AN, Pesaran T, DiStefano MT et al (2018) Recommendations for interpreting the loss of function PVS1 ACMG\/AMP variant criterion. Hum Mutat 39:1517\u20131524","journal-title":"Hum Mutat"},{"key":"5597_CR2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","volume":"229","author":"LJ Barber","year":"2013","unstructured":"Barber LJ, Sandhu S, Chen L et al (2013) Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 229:422\u2013429","journal-title":"J Pathol"},{"key":"5597_CR3","doi-asserted-by":"crossref","first-page":"D313","DOI":"10.1093\/nar\/gkw1132","volume":"45","author":"S Bienert","year":"2017","unstructured":"Bienert S, Waterhouse A, de Beer TA et al (2017) The SWISS-MODEL repository-new features and functionality. Nucleic Acids Res 45:D313\u2013D319","journal-title":"Nucleic Acids Res"},{"key":"5597_CR4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1078-0432.CCR-13-0225","volume":"20","author":"P Bouwman","year":"2014","unstructured":"Bouwman P, Jonkers J (2014) Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 20:540\u2013547","journal-title":"Clin Cancer Res"},{"key":"5597_CR5","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/2159-8290.CD-13-0094","volume":"3","author":"P Bouwman","year":"2013","unstructured":"Bouwman P, van der Gulden H, van der Heijden I et al (2013) A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov 3:1142\u20131155","journal-title":"Cancer Discov"},{"key":"5597_CR6","doi-asserted-by":"crossref","first-page":"pkaa029","DOI":"10.1093\/jncics\/pkaa029","volume":"4","author":"J Chen","year":"2020","unstructured":"Chen J, Bae E, Zhang L et al (2020) Penetrance of breast and ovarian cancer in women who carry a BRCA1\/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis. JNCI Cancer Spectr 4:pkaa029","journal-title":"JNCI Cancer Spectr"},{"key":"5597_CR7","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1093\/hmg\/ddu075","volume":"23","author":"M Colombo","year":"2014","unstructured":"Colombo M, Blok MJ, Whiley P et al (2014) Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Hum Mol Genet 23:3666\u20133680","journal-title":"Hum Mol Genet"},{"key":"5597_CR8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","volume":"31","author":"SM Domchek","year":"2013","unstructured":"Domchek SM, Bradbury A, Garber JE et al (2013) Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31:1267\u20131270","journal-title":"J Clin Oncol"},{"key":"5597_CR9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","volume":"20","author":"R Drost","year":"2011","unstructured":"Drost R, Bouwman P, Rottenberg S et al (2011) BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20:797\u2013809","journal-title":"Cancer Cell"},{"key":"5597_CR10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","volume":"61","author":"DF Easton","year":"1997","unstructured":"Easton DF, Steele L, Fields P et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 61:120\u2013128","journal-title":"Am J Hum Genet"},{"key":"5597_CR11","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","volume":"26","author":"DM Eccles","year":"2015","unstructured":"Eccles DM, Mitchell G, Monteiro AN et al (2015) BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol 26:2057\u20132065","journal-title":"Ann Oncol"},{"key":"5597_CR12","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards SL, Brough R, Lord CJ et al (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111\u20131115","journal-title":"Nature"},{"key":"5597_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103626","volume":"172","author":"D Fanale","year":"2022","unstructured":"Fanale D, Pivetti A, Cancelliere D et al (2022) BRCA1\/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: looking for the hidden meaning. Crit Rev Oncol Hematol 172:103626","journal-title":"Crit Rev Oncol Hematol"},{"key":"5597_CR14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP, Lubinski J, Moller P et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32:1547\u20131553","journal-title":"J Clin Oncol"},{"key":"5597_CR15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/path.5268","volume":"248","author":"E Fraile-Bethencourt","year":"2019","unstructured":"Fraile-Bethencourt E, Valenzuela-Palomo A, Diez-Gomez B et al (2019) Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays. J Pathol 248:409\u2013420","journal-title":"J Pathol"},{"key":"5597_CR16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391\u20132402","journal-title":"N Engl J Med"},{"key":"5597_CR17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41431-020-0612-1","volume":"28","author":"H Hoberg-Vetti","year":"2020","unstructured":"Hoberg-Vetti H, Ognedal E, Buisson A et al (2020) The intronic BRCA1 c.5407\u201325T>A variant causing partly skipping of exon 23-a likely pathogenic variant with reduced penetrance? Eur J Hum Genet 28:1078\u20131086","journal-title":"Eur J Hum Genet"},{"key":"5597_CR18","doi-asserted-by":"crossref","DOI":"10.5867\/medwave.2018.04.7160","volume":"18","author":"F Honold","year":"2018","unstructured":"Honold F, Camus M (2018) Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women\u2019s BRCA carriers. Medwave 18:e7161","journal-title":"Medwave"},{"key":"5597_CR19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s11596-022-2527-2","volume":"42","author":"PZ Hu","year":"2022","unstructured":"Hu PZ, Chen XY, Xiong W et al (2022) A BRCA1 splice site variant responsible for familial ovarian cancer in a Han\u2013Chinese family. Curr Med Sci 42:666\u2013672","journal-title":"Curr Med Sci"},{"key":"5597_CR20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs IJ, Menon U, Ryan A et al (2016) Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet 387:945\u2013956","journal-title":"Lancet"},{"key":"5597_CR21","doi-asserted-by":"crossref","first-page":"535.e24","DOI":"10.1016\/j.cell.2018.12.015","volume":"176","author":"K Jaganathan","year":"2019","unstructured":"Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF et al (2019) Predicting splicing from primary sequence with deep learning. Cell 176:535.e24-548.e24","journal-title":"Cell"},{"issue":"5","key":"5597_CR22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/genes12050780","volume":"12","author":"J Jimenez-Sainz","year":"2021","unstructured":"Jimenez-Sainz J, Jensen RB (2021) Imprecise medicine: BRCA2 variants of uncertain significance (VUS), the challenges and benefits to integrate a functional assay workflow with clinical decision rules. Genes (basel) 12(5):780","journal-title":"Genes (basel)"},{"key":"5597_CR23","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","volume":"110","author":"N Johnson","year":"2013","unstructured":"Johnson N, Johnson SF, Yao W et al (2013) Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A 110:17041\u201317046","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5597_CR24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A et al (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596:583\u2013589","journal-title":"Nature"},{"key":"5597_CR25","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402\u20132416","journal-title":"JAMA"},{"key":"5597_CR26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2016.71.3677","volume":"35","author":"S Lheureux","year":"2017","unstructured":"Lheureux S, Bruce JP, Burnier JV et al (2017) Somatic BRCA1\/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition. J Clin Oncol 35:1240\u20131249","journal-title":"J Clin Oncol"},{"key":"5597_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajhg.2017.01.004","volume":"100","author":"Q Li","year":"2017","unstructured":"Li Q, Wang K (2017) InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet 100:267\u2013280","journal-title":"Am J Hum Genet"},{"key":"5597_CR28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66\u201371","journal-title":"Science"},{"key":"5597_CR29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/jmedgenet-2012-100961","volume":"50","author":"S Moghadasi","year":"2013","unstructured":"Moghadasi S, Hofland N, Wouts JN et al (2013) Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling. J Med Genet 50:74\u201379","journal-title":"J Med Genet"},{"key":"5597_CR30","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495\u20132505","journal-title":"N Engl J Med"},{"key":"5597_CR31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41439-021-00140-2","volume":"8","author":"MM Moradian","year":"2021","unstructured":"Moradian MM, Babikyan DT, Markarian S et al (2021) Germline mutational spectrum in Armenian breast cancer patients suspected of hereditary breast and ovarian cancer. Hum Genome Var 8:9","journal-title":"Hum Genome Var"},{"key":"5597_CR32","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.celrep.2018.10.009","volume":"25","author":"J Nacson","year":"2018","unstructured":"Nacson J, Krais JJ, Bernhardy AJ et al (2018) BRCA1 mutation-specific responses to 53BP1 loss-induced homologous recombination and PARP inhibitor resistance. Cell Rep 25:1384","journal-title":"Cell Rep"},{"key":"5597_CR33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","volume":"29","author":"SM Noordermeer","year":"2019","unstructured":"Noordermeer SM, van Attikum H (2019) PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol 29:820\u2013834","journal-title":"Trends Cell Biol"},{"key":"5597_CR34","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1093\/hmg\/11.23.2805","volume":"11","author":"L Perrin-Vidoz","year":"2002","unstructured":"Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D et al (2002) The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11:2805\u20132814","journal-title":"Hum Mol Genet"},{"key":"5597_CR35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/10408363.2023.2234488","volume":"60","author":"G Ponti","year":"2023","unstructured":"Ponti G, De Angelis C, Ponti R et al (2023) Hereditary breast and ovarian cancer: from genes to molecular targeted therapies. Crit Rev Clin Lab Sci 60:640\u2013650","journal-title":"Crit Rev Clin Lab Sci"},{"key":"5597_CR36","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22:1055\u20131062","journal-title":"J Clin Oncol"},{"key":"5597_CR37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80\u201387","journal-title":"J Natl Cancer Inst"},{"key":"5597_CR38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/cmb.1997.4.311","volume":"4","author":"MG Reese","year":"1997","unstructured":"Reese MG, Eeckman FH, Kulp D et al (1997) Improved splice site detection in genie. J Comput Biol 4:311\u2013323","journal-title":"J Comput Biol"},{"key":"5597_CR39","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1038\/s41598-023-29452-9","volume":"13","author":"P Reuter","year":"2023","unstructured":"Reuter P, Walter M, Kohl S et al (2023) Systematic analysis of CNGA3 splice variants identifies different mechanisms of aberrant splicing. Sci Rep 13:2896","journal-title":"Sci Rep"},{"key":"5597_CR40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17:405\u2013424","journal-title":"Genet Med"},{"key":"5597_CR41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.breast.2017.03.006","volume":"33","author":"JM Ryu","year":"2017","unstructured":"Ryu JM, Kang G, Nam SJ et al (2017) Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from \u201cunknown significance\u201d to \u201cLikely pathogenic\u201d based on clinical evidence in Korea. Breast 33:109\u2013116","journal-title":"Breast"},{"key":"5597_CR42","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai W, Swisher EM, Karlan BY et al (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116\u20131120","journal-title":"Nature"},{"key":"5597_CR43","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1158\/1078-0432.CCR-09-2564","volume":"16","author":"DJ Sanz","year":"2010","unstructured":"Sanz DJ, Acedo A, Infante M et al (2010) A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast\/ovarian cancer patients. Clin Cancer Res 16:1957\u20131967","journal-title":"Clin Cancer Res"},{"key":"5597_CR44","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","volume":"38","author":"WP Tew","year":"2020","unstructured":"Tew WP, Lacchetti C, Ellis A et al (2020) PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 38:3468\u20133493","journal-title":"J Clin Oncol"},{"key":"5597_CR45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/path.5839","volume":"256","author":"A Valenzuela-Palomo","year":"2022","unstructured":"Valenzuela-Palomo A, Bueno-Martinez E, Sanoguera-Miralles L et al (2022) Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants. J Pathol 256:321\u2013334","journal-title":"J Pathol"},{"key":"5597_CR46","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi M, Anyango S, Deshpande M et al (2022) AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res 50:D439\u2013D444","journal-title":"Nucleic Acids Res"},{"key":"5597_CR47","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrg2164","volume":"8","author":"GS Wang","year":"2007","unstructured":"Wang GS, Cooper TA (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8:749\u2013761","journal-title":"Nat Rev Genet"},{"key":"5597_CR48","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse A, Bertoni M, Bienert S et al (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46:W296\u2013W303","journal-title":"Nucleic Acids Res"},{"key":"5597_CR49","first-page":"751","volume":"18","author":"N Weisschuh","year":"2012","unstructured":"Weisschuh N, Wissinger B, Gramer E (2012) A splice site mutation in the PAX6 gene which induces exon skipping causes autosomal dominant inherited aniridia. Mol vis 18:751\u2013757","journal-title":"Mol vis"},{"key":"5597_CR50","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789\u2013792","journal-title":"Nature"},{"key":"5597_CR51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/1066527041410418","volume":"11","author":"G Yeo","year":"2004","unstructured":"Yeo G, Burge CB (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11:377\u2013394","journal-title":"J Comput Biol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05597-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05597-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T22:02:41Z","timestamp":1711144961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05597-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["5597"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05597-y","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that there is no conflict of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"62"}}